Table 1 Correlations between clinicopathological characteristics and RBM3 mRNA (Cohort I) levels and protein expression (Cohort II)
Cohort I | Cohort II | ||||||
|---|---|---|---|---|---|---|---|
RBM3 score | low | high | 0 | 1 | 2 | ||
n (% for columns) | 120 (45.6) | 143 (54.4) | p-value | 74 (49.0) | 50 (33.1) | 27 (17.9) | p-value |
Histological subtype | |||||||
mucinuos | 0 (0.0) | 0 (0.0) | 0.887† | 4 (5.4) | 4 (8.0) | 3 (11.1) | 0.395† |
serous | 111 (92.5) | 133 (93.0) | 42 (56.8) | 31 (62.0) | 16 (59.3) | ||
endometroid | 9 (7.5) | 9 (6.3) | 17 (23.0) | 12 (24.0) | 5 (18.5) | ||
clear cell | 0 (0.0) | 0 (0.0) | 6 (8.1) | 1 (2.0) | 2 (7.4) | ||
Brenner | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (3.7) | ||
adenocarcinoma nos | 0 (0.0) | 1 (0.7) | 5 (6.8) | 2 (4.0) | 0 (0.0) | ||
Differentiation grade | |||||||
high | 3 (2.5) | 14 (9.8) | 0.079 | 2 (2.7) | 2 (4.0) | 3 (11.1) | 0.084 |
intermediate | 40 (33.3) | 48 (33.6) | 17 (23.0) | 13 (26.0) | 9 (33.3) | ||
low | 77 (64.2) | 78 (54.5) | 55 (74.3) | 35 (70.0) | 15 (55.6) | ||
missing | 0 (0.0) | 3 (2.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
Stage | |||||||
I | 9 (7.5) | 15 (10.5) | 0.070 | 14 (18.9) | 7 (14.0) | 5 (18.5) | 0.760 |
II | 3 (2.5) | 15 (10.5) | 5 (6.8) | 9 (18.0) | 3 (11.1) | ||
III | 101 (84.2) | 104 (72.7) | 40 (54.1) | 26 (52.0) | 8 (29.6) | ||
IV | 7 (5.8) | 9 (6.3) | 9 (12.2) | 6 (12.0) | 7 (25.9) | ||
missing | 0 (0.0) | 0 (0.0) | 6 (8.1) | 2 (4.0) | 4 (14.8) | ||